Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.60 |
| ▸ | CTSD | P07339 | 5/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.60 |
| ▸ | REN | P00797 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953319 | 0.89 | BACE1 (0.74) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL13953508 | 0.88 | BACE1 (0.60) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL8143848 | 0.88 | BACE1 (0.60) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL13953382 | 0.88 | BACE1 (0.60) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL4309479 | 0.87 | BACE1 (0.64) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL13264243 | 0.86 | BACE1 (0.73) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL8190062 | 0.86 | BACE1 (0.73) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL4311168 | 0.85 | BACE1 (0.82) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL13953468 | 0.85 | BACE1 (0.57) | BACE1CTSDBACE2RENCYP3A4 | |
| SCHEMBL4312576 | 0.83 | BACE1 (0.77) | BACE1CTSDBACE2RENAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885CTSD 88/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.